Carine Paturel

This inventor holds 25 USPTO granted patents and 26 published patent applications, plus 7 CIPO patents and 18 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Innate Pharma, Orega Biotech, Centre Leon Berard. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carine Paturel. Retrieved from https://idiyas.com/inventor/carine-paturel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 26)

% Patents Active = 88.0

CIPO Patents = 7 (Patent Applications = 13)

EPO Patents = 18 (Patent Applications = 31)

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 64(Granted Patents)

Location History:

Marcy l'Etoile, FR (2005 - 2024)
Marcy l'Étoile, FR (2019 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

CD73 Blocking Antibodies

NKp46 Binding Agents

Cancer Treatment

Inhibitory Pathways

KIR3DL2 Binding Agents

TLR3 Binding Agents

T Cell Lymphoma

Nucleic Acids

Antibody Chains

Plasmacytoid Dendritic Cells

Neutralization

Cancer Detection

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528876 - CD73 BLOCKING ANTIBODIES (2026-01-20),

2. 12448442 - Treatment of T cell lymphoma (2025-10-21),

3. 12365731 - NKp46 binding agents (2025-07-22),

4. 12202907 - Nucleic acids encoding and methods of producing proteins comprising antibody chains (2025-01-21),

5. 12037392 - Treatment regimens using anti-NKG2A antibodies (2024-07-16),

6. 11970535 - Treatment with anti-KIR3DL2 agents (2024-04-30),

7. 11958907 - CD73 blockade (2024-04-16),

8. 11858990 - KIR3DL2 binding agents (2024-01-02),

9. 11578136 - Compositions and methods for treating cancer (2023-02-14),

10. 11572410 - Neutralization of inhibitory pathways in lymphocytes (2023-02-07),

11. 11377503 - Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide (2022-07-05),

12. 11377492 - NKp46 binding agents (2022-07-05),

13. 11130817 - CD73 blocking agents (2021-09-28),

14. 10870700 - Neutralization of inhibitory pathways in lymphocytes (2020-12-22),

15. 10766966 - CD73 blockade (2020-09-08),

Title: Inventor Carine Paturel: Revolutionizing the Field of Biotechnology

Introduction: Carine Paturel, a pioneering inventor hailing from Marcy l'Etoile, France, has made significant contributions to the field of biotechnology through her innovative creations and patents.

Latest Patents: Carine Paturel's most recent patents focus on novel methods for enhancing drug delivery systems, particularly in the realm of targeted cancer therapies. These patents showcase her dedication to advancing medical technology for the benefit of patients worldwide.

Career Highlights: With a career spanning over two decades, Carine Paturel has established herself as a leading figure in the biotechnology industry. Her groundbreaking inventions have not only garnered international recognition but have also paved the way for new developments in the field.

Collaborations: Throughout her career, Carine Paturel has collaborated with renowned research institutions and pharmaceutical companies to further her innovative projects. These collaborations have been instrumental in bringing her inventions to fruition and making a tangible impact on the healthcare sector.

Conclusion: Carine Paturel's unwavering commitment to innovation and her passion for improving patient outcomes have solidified her reputation as a trailblazer in the field of biotechnology. Her continued dedication to pushing the boundaries of scientific discovery serves as an inspiration to aspiring inventors and researchers worldwide.

Profile summary based on public USPTO records.